Illumina has notched approval from the China National Drug Administration to market and sell its MiSeqDx sequencing system to hospitals and other medical institutions throughout the country.
“We are encouraging more clinical companies to select the MiSeqDx System to develop new clinical assays and to help provide needed solutions to some of China’s greatest health challenges,” Garret Hampton, executive vice president of clinical genomics at Illumina, said in a statement.
MiSeqDx is used for in-vitro diagnostic testing, designed specifically for the clinical laboratory environment. It’s also approved in the United States, China, Canada, Argentina, European countries, Australia, South Korea, Singapore, Thailand and the Philippines.
Illumina has already entered the Chinese market and inked deals with Chinese firms, including earlier this year partnering with KingMed Diagnostics to develop oncology and hereditary disease tests.